science is motivated by the need to provide effective treatments
to the right patients at the right doses for a specific disease
indication). The term is used mostly in the health sciences and refers to
real-time translation of bench science, conducted only
in a lab, to bedside clinical practice or dissemination to
population-based community interventions. (Source: NIH)
Breast Cancer Consortium
ABRCC Researcher Spotlight:
MEET Dr. Peter Kabos, M.D
Dr. Peter Kabos is Assistant Professor, Division of Medical Oncology at
University of Colorado Cancer Center.
Dr. Kabos joined the UCD
faculty in July 2009 and is a member of the breast oncology program
there. He spent four years as a post-doctoral research fellow at
Cedars-Sinai Medical Center studying the biology of normal and cancer
stem cells in gliomas. He completed his Internal Medicine residency
training at USC Keck School of Medicine in Los Angeles and a fellowship
in Hematology/Oncology at the University of Colorado Denver. He received
his MD from Comenius University, Slovakia.
Publications from Dr. Kabos on PubMed.gov
His research focus is in
translating preclinical findings into novel treatments for patients with
breast cancer. The Kabos
Research Lab at the university focuses on hormone receptive positive
breast cancer, the role of breast cancer stem cells and tumor
microenvironment in treatment resistance.
Cancer Network Case File
His specialties and certifications include: Internal Medicine, Board
Certification (2006); Internal Medicine - Medical Oncology, Board
Certification (2009). His awards and honors include the ASCO Young
Investigator Award and NIH/NCI K08 Career Development Award.
About University of
Colorado Cancer Center
The University of Colorado Cancer Center is the Rocky Mountain region's
only National Cancer Institute-designated comprehensive cancer center.
NCI has given only 40 cancer centers this designation, deeming membership
as "the best of the best."
Learn more at: UC
Denver School of Medicine